文献速递泌尿生殖MR

前列腺癌中PTEN表达与临床病理特征及多参数MRI表现的关系

PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings.
PubMed 文献 · AJR Am J Roentgenol · 2019-03-19

纳入43例接受根治性前列腺切除术的前列腺癌患者,在治疗前MRI上勾画索引肿瘤并测定ADC及DCE-MRI药代动力学参数(Ktrans、kep、ve、vp),用珠阵列和RT-qPCR检测肿瘤穿刺标本的PTEN表达。珠阵列(p=0.006)和RT-qPCR(p=0.03)均显示低PTEN表达肿瘤的ADC显著更低;PTEN表达与淋巴结转移呈负相关(珠阵列p=0.008;RT-qPCR p<0.001);珠阵列显示PTEN表达与前列腺外侵犯(p=0.048)和Gleason评分(p=0.028)存在弱但显著的关联;DCE参数与PTEN表达及临床病理特征均无关联。作者认为DWI-derived ADC可能有助于筛选因PTEN缺陷而具有潜在侵袭性肿瘤的患者。

要点

  • 低PTEN表达的前列腺癌在DWI上ADC显著更低(珠阵列p=0.006;RT-qPCR p=0.03)。
  • PTEN表达与淋巴结转移呈负相关(珠阵列p=0.008;RT-qPCR p<0.001)。
  • DCE-MRI药代动力学参数与PTEN表达及临床病理特征均无关联。

核心结论

  • DWI-derived ADC可能有助于筛选因PTEN缺陷而具有潜在侵袭性肿瘤的前列腺癌患者。

研究设计与样本

  • 研究纳入43例接受根治性前列腺切除术的前列腺癌患者,在治疗前MRI上识别索引肿瘤并与组织病理学结果最佳对应区域勾画,测定DWI的ADC及基于扩展Tofts模型的DCE-MRI药代动力学参数(Ktrans、kep、ve、vp),并用珠阵列和RT-qPCR检测肿瘤穿刺标本的PTEN表达。

关键影像表现/征象

  • 低PTEN表达肿瘤的ADC显著更低(珠阵列p=0.006;RT-qPCR p=0.03)。
  • ADC与Gleason评分呈负相关(p=0.001),与肿瘤大小呈负相关(p=0.023)。
  • DCE-MRI参数(Ktrans、kep、ve、vp)与PTEN表达及临床病理特征均无关联。

诊断标准与关键数值

  • 低PTEN表达肿瘤ADC显著更低:珠阵列p=0.006,RT-qPCR p=0.03。
  • PTEN表达与淋巴结转移负相关:珠阵列p=0.008,RT-qPCR p<0.001。
  • 珠阵列显示PTEN表达与前列腺外侵犯(p=0.048)和Gleason评分(p=0.028)存在弱但显著的关联。

临床应用与阅片要点

  • 阅片时可关注DWI-derived ADC值,低ADC可能提示PTEN表达降低及潜在侵袭性肿瘤。
  • DCE-MRI药代动力学参数在本研究中未显示与PTEN表达或临床病理特征的关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The objective of our study was to investigate whether phosphatase and tensin homolog (PTEN) expression is associated with clinicopathologic features and multiparametric MRI findings in prostate cancer. MATERIALS AND METHODS. Forty-three patients with prostate cancer who underwent radical prostatectomy were included. Index tumor was identified on pretreatment MRI and delineated in the area that correlated best with histopathology results. The apparent diffusion coefficient (ADC) from DWI and pharmacokinetic parameters derived from dynamic contrast-enhanced MRI (DCE-MRI) using the extended Tofts model (Ktrans, kep, ve, and vp) within the tumor were estimated. The following clinicopathologic parameters were assessed: pretreatment serum levels of prostate-specific antigen, disseminated tumor cell status, age, Gleason score, tumor size, extraprostatic extension (EPE), tumor location, and lymph node metastases. Gene expression profiles were acquired in biopsies from the tumor using bead arrays, and validated using reverse transcription quantitative polymerase chain reaction (RT-qPCR) on a different part of the biopsy. RESULTS. Based on bead arrays (p = 0.006) and RT-qPCR (p = 0.03) data, a significantly lower ADC was found in tumors with low PTEN expression. Moreover, PTEN expression was negatively associated with lymph node metastases (bead arrays, p = 0.008; RT-qPCR, p < 0.001). A weak but significant association between PTEN expression, EPE (p = 0.048), and Gleason score (p = 0.028) was revealed on bead arrays. ADC was negatively correlated with Gleason score (p = 0.001) and tumor size (p = 0.023). No association among DCE parameters, PTEN expression, and clinicopathologic features was found. CONCLUSION. ADC derived from DWI may be useful in selecting patients with potentially aggressive tumor caused by PTEN deficiency.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Switlyk MD, Salberg UB, Geier OM, et al. PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings. AJR Am J Roentgenol. 2019. PMID: 30888866. doi:10.2214/AJR.18.20743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。